This year's American Society of Clinical Oncology (ASCO) conference has been a subdued affair for European pharmaceutical companies, with no major plenary presentations and little data capable of moving share prices materially. But beneath the quiet surface, both AstraZeneca PLC (LSE:AZN, NASDAQ:AZN) and Roche emerged with important questions to answer about the commercial futures of key pipeline assets.